Sera Prognostics, Inc. (NASDAQ: SERA) Stock Competitors & Peer Comparison
See SERA's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for SERA and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SERA | $2.00 | +0.06% | 76M | -3.06 | -$0.65 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.69% |
| TMO | $647.89 | +5.67% | 238.4B | 27.70 | $23.16 | +0.29% |
| DHR | $209.36 | +3.01% | 147.1B | 26.23 | $7.98 | +0.69% |
| NTRA | $349.44 | +2.24% | 50.2B | -265.74 | -$1.32 | N/A |
| IQV | $270.94 | +1.98% | 44.4B | 22.22 | $12.13 | N/A |
| A | $153.58 | +4.62% | 42.4B | 25.85 | $5.81 | +0.67% |
| IDXX | $519.83 | +2.02% | 40.3B | 35.92 | $14.22 | N/A |
| ILMN | $228.00 | +9.51% | 33.6B | 44.19 | $5.03 | N/A |
| WAT | $420.59 | +2.58% | 31.2B | 30.49 | $13.68 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
SERA vs DHR-PB Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, SERA's ROE is -0.47%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, SERA is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for SERA.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
SERA vs TMO Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, TMO has a market cap of 238.4B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while TMO trades at $647.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas TMO's P/E ratio is 27.70. In terms of profitability, SERA's ROE is -0.47%, compared to TMO's ROE of +0.13%. Regarding short-term risk, SERA is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for SERA.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
SERA vs DHR Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, DHR has a market cap of 147.1B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while DHR trades at $209.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas DHR's P/E ratio is 26.23. In terms of profitability, SERA's ROE is -0.47%, compared to DHR's ROE of +0.08%. Regarding short-term risk, SERA is less volatile compared to DHR. This indicates lower risk in terms of short-term price fluctuations for SERA.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
SERA vs NTRA Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, NTRA has a market cap of 50.2B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while NTRA trades at $349.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas NTRA's P/E ratio is -265.74. In terms of profitability, SERA's ROE is -0.47%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, SERA is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for SERA.Check NTRA's competition here
IQVIA Holdings Inc. (NYSE: IQV)
SERA vs IQV Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, IQV has a market cap of 44.4B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while IQV trades at $270.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas IQV's P/E ratio is 22.22. In terms of profitability, SERA's ROE is -0.47%, compared to IQV's ROE of +0.22%. Regarding short-term risk, SERA is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for SERA.Check IQV's competition here
Agilent Technologies, Inc. (NYSE: A)
SERA vs A Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, A has a market cap of 42.4B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while A trades at $153.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas A's P/E ratio is 25.85. In terms of profitability, SERA's ROE is -0.47%, compared to A's ROE of +0.20%. Regarding short-term risk, SERA is less volatile compared to A. This indicates lower risk in terms of short-term price fluctuations for SERA.Check A's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
SERA vs IDXX Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, IDXX has a market cap of 40.3B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while IDXX trades at $519.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas IDXX's P/E ratio is 35.92. In terms of profitability, SERA's ROE is -0.47%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, SERA is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for SERA.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
SERA vs ILMN Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, ILMN has a market cap of 33.6B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while ILMN trades at $228.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas ILMN's P/E ratio is 44.19. In terms of profitability, SERA's ROE is -0.47%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, SERA is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for SERA.Check ILMN's competition here
Waters Corporation (NYSE: WAT)
SERA vs WAT Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, WAT has a market cap of 31.2B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while WAT trades at $420.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas WAT's P/E ratio is 30.49. In terms of profitability, SERA's ROE is -0.47%, compared to WAT's ROE of +0.02%. Regarding short-term risk, SERA is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for SERA.Check WAT's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
SERA vs DGX Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, DGX has a market cap of 27.3B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while DGX trades at $246.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas DGX's P/E ratio is 24.39. In terms of profitability, SERA's ROE is -0.47%, compared to DGX's ROE of +0.14%. Regarding short-term risk, SERA is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for SERA.Check DGX's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
SERA vs MTD Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, MTD has a market cap of 26.9B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while MTD trades at $1,376.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas MTD's P/E ratio is 30.58. In terms of profitability, SERA's ROE is -0.47%, compared to MTD's ROE of -12.00%. Regarding short-term risk, SERA is less volatile compared to MTD. This indicates lower risk in terms of short-term price fluctuations for SERA.Check MTD's competition here
Labcorp Holdings Inc. (NYSE: LH)
SERA vs LH Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, LH has a market cap of 25.9B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while LH trades at $324.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas LH's P/E ratio is 18.72. In terms of profitability, SERA's ROE is -0.47%, compared to LH's ROE of +0.12%. Regarding short-term risk, SERA is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for SERA.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
SERA vs GH Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, GH has a market cap of 23.6B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while GH trades at $176.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas GH's P/E ratio is -50.33. In terms of profitability, SERA's ROE is -0.47%, compared to GH's ROE of +2.11%. Regarding short-term risk, SERA is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for SERA.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
SERA vs EXAS Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas EXAS's P/E ratio is -95.37. In terms of profitability, SERA's ROE is -0.47%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, SERA is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for SERA.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
SERA vs MEDP Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, MEDP has a market cap of 17.3B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while MEDP trades at $618.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas MEDP's P/E ratio is 36.37. In terms of profitability, SERA's ROE is -0.47%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, SERA is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for SERA.Check MEDP's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
SERA vs ILMNV Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas ILMNV's P/E ratio is N/A. In terms of profitability, SERA's ROE is -0.47%, compared to ILMNV's ROE of N/A. Regarding short-term risk, SERA is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for SERA.Check ILMNV's competition here
Revvity, Inc. (NYSE: RVTY)
SERA vs RVTY Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, RVTY has a market cap of 15.6B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while RVTY trades at $145.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas RVTY's P/E ratio is 26.19. In terms of profitability, SERA's ROE is -0.47%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, SERA is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for SERA.Check RVTY's competition here
PerkinElmer, Inc. (NYSE: PKI)
SERA vs PKI Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas PKI's P/E ratio is 41.45. In terms of profitability, SERA's ROE is -0.47%, compared to PKI's ROE of +0.03%. Regarding short-term risk, SERA is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for SERA.Check PKI's competition here
ICON Public Limited Company (NASDAQ: ICLR)
SERA vs ICLR Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, ICLR has a market cap of 13.2B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while ICLR trades at $174.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas ICLR's P/E ratio is 14.07. In terms of profitability, SERA's ROE is -0.47%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, SERA is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for SERA.Check ICLR's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
SERA vs CRL Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, CRL has a market cap of 13.1B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while CRL trades at $279.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas CRL's P/E ratio is 27.53. In terms of profitability, SERA's ROE is -0.47%, compared to CRL's ROE of -0.08%. Regarding short-term risk, SERA is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for SERA.Check CRL's competition here
Qiagen N.V. (NYSE: QGEN)
SERA vs QGEN Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, QGEN has a market cap of 8.8B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while QGEN trades at $43.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas QGEN's P/E ratio is 17.55. In terms of profitability, SERA's ROE is -0.47%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, SERA is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for SERA.Check QGEN's competition here
RadNet, Inc. (NASDAQ: RDNT)
SERA vs RDNT Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, RDNT has a market cap of 6.1B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while RDNT trades at $77.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas RDNT's P/E ratio is 167.65. In terms of profitability, SERA's ROE is -0.47%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, SERA is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for SERA.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
SERA vs SHC Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, SHC has a market cap of 5.4B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while SHC trades at $19.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas SHC's P/E ratio is 19.77. In terms of profitability, SERA's ROE is -0.47%, compared to SHC's ROE of +0.27%. Regarding short-term risk, SERA is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for SERA.Check SHC's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
SERA vs BLLN Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, BLLN has a market cap of 4.8B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while BLLN trades at $105.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas BLLN's P/E ratio is 148.96. In terms of profitability, SERA's ROE is -0.47%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, SERA is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for SERA.Check BLLN's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
SERA vs SYNH Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas SYNH's P/E ratio is 61.40. In terms of profitability, SERA's ROE is -0.47%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, SERA is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for SERA.Check SYNH's competition here
GRAIL Inc. (NASDAQ: GRAL)
SERA vs GRAL Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, GRAL has a market cap of 3.3B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while GRAL trades at $76.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas GRAL's P/E ratio is -7.78. In terms of profitability, SERA's ROE is -0.47%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, SERA is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for SERA.Check GRAL's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
SERA vs OLK Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas OLK's P/E ratio is -96.59. In terms of profitability, SERA's ROE is -0.47%, compared to OLK's ROE of -0.07%. Regarding short-term risk, SERA is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for SERA.Check OLK's competition here
Veracyte, Inc. (NASDAQ: VCYT)
SERA vs VCYT Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, VCYT has a market cap of 3.2B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while VCYT trades at $40.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas VCYT's P/E ratio is 20.07. In terms of profitability, SERA's ROE is -0.47%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, SERA is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for SERA.Check VCYT's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
SERA vs WGS Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, WGS has a market cap of 2.8B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while WGS trades at $98.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas WGS's P/E ratio is 262.89. In terms of profitability, SERA's ROE is -0.47%, compared to WGS's ROE of -0.39%. Regarding short-term risk, SERA is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for SERA.Check WGS's competition here
CareDx, Inc (NASDAQ: CDNA)
SERA vs CDNA Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, CDNA has a market cap of 2.7B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while CDNA trades at $54.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas CDNA's P/E ratio is 62.67. In terms of profitability, SERA's ROE is -0.47%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, SERA is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for SERA.Check CDNA's competition here
Personalis, Inc. (NASDAQ: PSNL)
SERA vs PSNL Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while PSNL trades at $16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas PSNL's P/E ratio is -14.77. In terms of profitability, SERA's ROE is -0.47%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, SERA is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for SERA.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
SERA vs OPK Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while OPK trades at $1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas OPK's P/E ratio is -5.81. In terms of profitability, SERA's ROE is -0.47%, compared to OPK's ROE of -0.06%. Regarding short-term risk, SERA is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for SERA.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
SERA vs CSTL Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, CSTL has a market cap of 1.1B. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while CSTL trades at $35.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas CSTL's P/E ratio is -53.79. In terms of profitability, SERA's ROE is -0.47%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, SERA is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for SERA.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
SERA vs FLGT Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, FLGT has a market cap of 604.4M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while FLGT trades at $21.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas FLGT's P/E ratio is 2128.00. In terms of profitability, SERA's ROE is -0.47%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, SERA is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for SERA.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
SERA vs GRALV Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas GRALV's P/E ratio is N/A. In terms of profitability, SERA's ROE is -0.47%, compared to GRALV's ROE of N/A. Regarding short-term risk, SERA is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for SERA.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
SERA vs NEO Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, NEO has a market cap of 485.4M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while NEO trades at $19.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas NEO's P/E ratio is 145.31. In terms of profitability, SERA's ROE is -0.47%, compared to NEO's ROE of -0.06%. Regarding short-term risk, SERA is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for SERA.Check NEO's competition here
Global Cord Blood Corporation (NYSE: CO)
SERA vs CO Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas CO's P/E ratio is 5.06. In terms of profitability, SERA's ROE is -0.47%, compared to CO's ROE of +0.11%. Regarding short-term risk, SERA is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for SERA.Check CO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
SERA vs MYGN Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, MYGN has a market cap of 366.5M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while MYGN trades at $4.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas MYGN's P/E ratio is -29.85. In terms of profitability, SERA's ROE is -0.47%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, SERA is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for SERA.Check MYGN's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
SERA vs FLDM Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas FLDM's P/E ratio is -4.74. In terms of profitability, SERA's ROE is -0.47%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, SERA is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for SERA.Check FLDM's competition here
Prenetics Global Limited (NASDAQ: PRENW)
SERA vs PRENW Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, PRENW has a market cap of 277.8M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas PRENW's P/E ratio is N/A. In terms of profitability, SERA's ROE is -0.47%, compared to PRENW's ROE of -0.49%. Regarding short-term risk, SERA is less volatile compared to PRENW. This indicates lower risk in terms of short-term price fluctuations for SERA.Check PRENW's competition here
Biodesix, Inc. (NASDAQ: BDSX)
SERA vs BDSX Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, BDSX has a market cap of 225.5M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while BDSX trades at $28.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas BDSX's P/E ratio is -8.74. In terms of profitability, SERA's ROE is -0.47%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, SERA is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for SERA.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
SERA vs XGN Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, XGN has a market cap of 181M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while XGN trades at $7.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas XGN's P/E ratio is -9.25. In terms of profitability, SERA's ROE is -0.47%, compared to XGN's ROE of -1.22%. Regarding short-term risk, SERA is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for SERA.Check XGN's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
SERA vs IMDX Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, IMDX has a market cap of 129.8M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while IMDX trades at $3.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas IMDX's P/E ratio is -2.70. In terms of profitability, SERA's ROE is -0.47%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, SERA is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for SERA.Check IMDX's competition here
Genetron Holdings Limited (NASDAQ: GTH)
SERA vs GTH Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas GTH's P/E ratio is -1.11. In terms of profitability, SERA's ROE is -0.47%, compared to GTH's ROE of -1.01%. Regarding short-term risk, SERA is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for SERA.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
SERA vs GENE Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas GENE's P/E ratio is -38.25. In terms of profitability, SERA's ROE is -0.47%, compared to GENE's ROE of -1.85%. Regarding short-term risk, SERA is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for SERA.Check GENE's competition here
Precipio, Inc. (NASDAQ: PRPO)
SERA vs PRPO Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, PRPO has a market cap of 48.6M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while PRPO trades at $25.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas PRPO's P/E ratio is -104.77. In terms of profitability, SERA's ROE is -0.47%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, SERA is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for SERA.Check PRPO's competition here
MDxHealth S.A. (NASDAQ: MDXH)
SERA vs MDXH Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, MDXH has a market cap of 34.6M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while MDXH trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas MDXH's P/E ratio is -1.77. In terms of profitability, SERA's ROE is -0.47%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, SERA is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for SERA.Check MDXH's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
SERA vs QUCY Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, QUCY has a market cap of 30.5M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while QUCY trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas QUCY's P/E ratio is -0.06. In terms of profitability, SERA's ROE is -0.47%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, SERA is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for SERA.Check QUCY's competition here
Akumin Inc. (NASDAQ: AKU)
SERA vs AKU Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas AKU's P/E ratio is -0.13. In terms of profitability, SERA's ROE is -0.47%, compared to AKU's ROE of -5.32%. Regarding short-term risk, SERA is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for SERA.Check AKU's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
SERA vs CEMI Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas CEMI's P/E ratio is -0.63. In terms of profitability, SERA's ROE is -0.47%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, SERA is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for SERA.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
SERA vs ENZ Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas ENZ's P/E ratio is -2.24. In terms of profitability, SERA's ROE is -0.47%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, SERA is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for SERA.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
SERA vs PMD Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas PMD's P/E ratio is -5.24. In terms of profitability, SERA's ROE is -0.47%, compared to PMD's ROE of -0.32%. Regarding short-term risk, SERA is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for SERA.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
SERA vs ME Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas ME's P/E ratio is -0.03. In terms of profitability, SERA's ROE is -0.47%, compared to ME's ROE of -42.03%. Regarding short-term risk, SERA is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for SERA.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
SERA vs MYNZ Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, SERA's ROE is -0.47%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, SERA is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for SERA.Check MYNZ's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
SERA vs BNR Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, BNR has a market cap of 12.2M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while BNR trades at $13.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas BNR's P/E ratio is -13.29. In terms of profitability, SERA's ROE is -0.47%, compared to BNR's ROE of -0.13%. Regarding short-term risk, SERA is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for SERA.Check BNR's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
SERA vs ADVB Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, ADVB has a market cap of 11.2M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while ADVB trades at $8.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas ADVB's P/E ratio is -73.45. In terms of profitability, SERA's ROE is -0.47%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, SERA is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for SERA.Check ADVB's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
SERA vs CHEK Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas CHEK's P/E ratio is -0.43. In terms of profitability, SERA's ROE is -0.47%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, SERA is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for SERA.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
SERA vs CNTG Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas CNTG's P/E ratio is -0.23. In terms of profitability, SERA's ROE is -0.47%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, SERA is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for SERA.Check CNTG's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
SERA vs NDRA Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, NDRA has a market cap of 7.3M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while NDRA trades at $5.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas NDRA's P/E ratio is -0.73. In terms of profitability, SERA's ROE is -0.47%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, SERA is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for SERA.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
SERA vs APDN Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas APDN's P/E ratio is -0.10. In terms of profitability, SERA's ROE is -0.47%, compared to APDN's ROE of -7.23%. Regarding short-term risk, SERA is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for SERA.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
SERA vs NVTA Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas NVTA's P/E ratio is -0.00. In terms of profitability, SERA's ROE is -0.47%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, SERA is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for SERA.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
SERA vs LMDXW Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, SERA's ROE is -0.47%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, SERA is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for SERA.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
SERA vs LMDX Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas LMDX's P/E ratio is -0.01. In terms of profitability, SERA's ROE is -0.47%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, SERA is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for SERA.Check LMDX's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
SERA vs BIAFW Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, BIAFW has a market cap of 4.6M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while BIAFW trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas BIAFW's P/E ratio is 0.49. In terms of profitability, SERA's ROE is -0.47%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, SERA is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for SERA.Check BIAFW's competition here
DermTech, Inc. (NASDAQ: DMTK)
SERA vs DMTK Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas DMTK's P/E ratio is -0.04. In terms of profitability, SERA's ROE is -0.47%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, SERA is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for SERA.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
SERA vs NOTV Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas NOTV's P/E ratio is -0.03. In terms of profitability, SERA's ROE is -0.47%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, SERA is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for SERA.Check NOTV's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
SERA vs BIAF Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, BIAF has a market cap of 2.6M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while BIAF trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas BIAF's P/E ratio is -0.73. In terms of profitability, SERA's ROE is -0.47%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, SERA is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for SERA.Check BIAF's competition here
SeqLL Inc. (NASDAQ: SQL)
SERA vs SQL Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas SQL's P/E ratio is -0.40. In terms of profitability, SERA's ROE is -0.47%, compared to SQL's ROE of -30.46%. Regarding short-term risk, SERA is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for SERA.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
SERA vs AWH Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas AWH's P/E ratio is -0.09. In terms of profitability, SERA's ROE is -0.47%, compared to AWH's ROE of +1.62%. Regarding short-term risk, SERA is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for SERA.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
SERA vs HTGM Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas HTGM's P/E ratio is -0.03. In terms of profitability, SERA's ROE is -0.47%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, SERA is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for SERA.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
SERA vs BIOC Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas BIOC's P/E ratio is -0.01. In terms of profitability, SERA's ROE is -0.47%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, SERA is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for SERA.Check BIOC's competition here
iSpecimen Inc. (NASDAQ: ISPC)
SERA vs ISPC Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, ISPC has a market cap of 184.7K. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while ISPC trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas ISPC's P/E ratio is -0.04. In terms of profitability, SERA's ROE is -0.47%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, SERA is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for SERA.Check ISPC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
SERA vs SQLLW Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, SERA's ROE is -0.47%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, SERA is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for SERA.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
SERA vs WGSWW Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, SERA's ROE is -0.47%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, SERA is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for SERA.Check WGSWW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
SERA vs BNGOW Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas BNGOW's P/E ratio is N/A. In terms of profitability, SERA's ROE is -0.47%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, SERA is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for SERA.Check BNGOW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
SERA vs PRXL Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas PRXL's P/E ratio is 42.97. In terms of profitability, SERA's ROE is -0.47%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, SERA is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for SERA.Check PRXL's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
SERA vs MEUSW Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas MEUSW's P/E ratio is N/A. In terms of profitability, SERA's ROE is -0.47%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, SERA is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for SERA.Check MEUSW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
SERA vs NDRAW Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas NDRAW's P/E ratio is N/A. In terms of profitability, SERA's ROE is -0.47%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, SERA is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for SERA.Check NDRAW's competition here
Danaher Corporation (NYSE: DHR-PA)
SERA vs DHR-PA Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, SERA's ROE is -0.47%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, SERA is less volatile compared to DHR-PA. This indicates lower risk in terms of short-term price fluctuations for SERA.Check DHR-PA's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
SERA vs CHEKZ Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, SERA's ROE is -0.47%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, SERA is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for SERA.Check CHEKZ's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
SERA vs OCDX Comparison September 2026
Sera Prognostics, Inc. (NASDAQ: SERA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SERA stands at 76M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, SERA is priced at $2.00 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SERA currently has a P/E ratio of -3.06, whereas OCDX's P/E ratio is -42.28. In terms of profitability, SERA's ROE is -0.47%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, SERA is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for SERA.Check OCDX's competition here